Cannabidiol (CBD) has gained significant attention for its potential therapeutic benefits, but its safety profile in healthy populations remains underexplored. This systematic review and meta-analysis aim to evaluate the safety of CBD compared to placebo in healthy adults. A comprehensive search of PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov identified four randomized controlled trials (RCTs) involving 269 healthy adults. The primary outcome was headache, with secondary outcomes including fatigue, abdominal pain, diarrhea, upper respiratory tract infection (URTI), and dizziness. The results revealed that CBD use was associated with a significantly higher risk of diarrhea (RR = 5.85; 95% CI = 1.14–30.02; P = 0.03). While there was a trend toward increased abdominal pain and headache, these results were not statistically significant. Fatigue, dizziness, and URTI showed no significant differences between the CBD and placebo groups. These findings suggest that while CBD appears safe for short-term use in healthy adults, gastrointestinal side effects, particularly diarrhea, should be monitored. Further large-scale studies with longer follow-up periods are warranted to confirm these results and explore long-term safety.

The significance of mental health in athletes is acknowledged and valued. This review explores psychosocial triggers, evolving screening approaches, digital mood-tracking tools, and embedded mental health professionals in performance programs. Numerous studies have shown that the occurrence of depressive symptoms and anxiety is common among high performance athletes. Recent systematic reviews confirm anxiety, depression, and distress rates of 20–35%, especially around injury, deselection, or career change. In this article, we aim to focus on psychiatric issues faced by athletes and propose strategies that would help in improving mental health. Several reasons that affect the mental health of this population have been highlighted. The lack of proper mental health support, no access to sports psychologists in the training programs need urgent attention. A key point is that team support and self-confidence can also help buffer the negative effects of perfectionism on anxiety and performance.

Background: Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are leading causes of chronic liver disease worldwide. Despite the rising clinical burden, there are currently no approved pharmacologic therapies. Semaglutide, a glucagon-like peptide-1 receptor agonist with established metabolic and weight-loss benefits, is being evaluated for potential disease-modifying effects in NAFLD/NASH. Objective: To assess the efficacy and tolerability of subcutaneous semaglutide versus placebo in adults with NAFLD or NASH, focusing on biochemical, histologic, metabolic, and safety outcomes. Methods: We conducted a systematic review and meta-analysis of placebo-controlled randomized controlled trials evaluating subcutaneous semaglutide in adults (≥18 years) with NAFLD or NASH diagnosed by imaging, histology, and/or biochemical markers. PubMed, CENTRAL, and Scopus were searched from inception to May 15, 2025 using predefined terms related to semaglutide and fatty liver disease. Two independent assessors extracted data and evaluated risk of bias using the Cochrane RoB 2 tool, while certainty of evidence was appraised with Grading of Recommendations, Assessment, Development, and Evaluation. Pooled effect estimates were calculated using a random-effects model and reported as risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Results: Semaglutide significantly reduced liver enzymes, including aspartate aminotransferase (MD = −6.72 U/L, 95% CI = −11.79 to −1.64; P = .009). Histologically, semaglutide more than doubled the likelihood of NASH resolution without fibrosis progression (RR = 2.14, 95% CI = 1.44–3.17; P = .0002). Improvement in fibrosis stage was not statistically significant (RR = 1.14, 95% CI = 0.63–2.05; P = .67), though the direction of effect favored semaglutide. Metabolic outcomes showed substantial benefits, including weight loss (MD = −6.99%, 95% CI = −13.92 to −0.06; P = .05) and improved glycated hemoglobin (MD = −1.29%, 95% CI = −1.46 to −1.13; P < .00001). Gastrointestinal adverse events and treatment discontinuation occurred more frequently with semaglutide, while serious adverse events were comparable to placebo (95% CI = 0.81–1.41; P = .64; P = .65). Conclusion: Semaglutide demonstrates promising efficacy for NASH resolution and meaningful metabolic improvement with an overall acceptable safety profile. Its effect on fibrosis remains uncertain, and longer-term, adequately powered trials are needed to clarify its role in NAFLD/NASH treatment.

Was not provided for this article.

Was not provided for this article.